



# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

Carmen Medina, MPH, Ph.D. (c)  
Vice President, Technical  
PAREXEL International

# Roadmap

## ENTERPRISE-WIDE QUALITY METRICS

### I. Understand FDA's Quality Metrics Initiative relative to

- cGMP Requirements
- Enterprise-wide Quality Systems

### II. Apply Metrics and Statistics Throughout Lifecycle Process Validation

### III. Design a Framework for an Entire Platform of Agile Analytics

- Use metrics, data and statistical analysis for empowered decision-making
- Connect metrics and data directly to its center of control
- Create a synergistic relationship between data and personnel

**Enterprise-wide analytics provides a 360° feedback-loop of typically siloed data, while fostering predictability, detection, rapid accountability, targeted risk mitigation and continuous improvement.**

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### YOUR PROGRAM SHOULD OFFER ALL LEVELS OF PERSONNEL REAL-TIME

- ◆ PROACTIVE MANAGEMENT
- ◆ DETECTABILITY
- ◆ PREDICTABILITY
- ◆ RISK MITIGATION
- ◆ CONTINUOUS IMPROVEMENT
- ◆ EMPOWERED DECISION MAKING



# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### QUALITY METRICS OPPORTUNITIES ACROSS PRODUCT DEVELOPMENT AND COMMERCIALIZATION STAGES

#### UPSTREAM QUALITY METRICS

##### Goal for New Products:

- ✦ Provide Quality Guideposts supporting Speed to Market

#### MIDSTREAM QUALITY METRICS

##### Goals for New Products:

- ✦ Eliminate Submission Roadblocks
- ✦ Statistically establish Optimal Operating Conditions

##### Goals for Legacy Products:

- ✦ Refine Process Control
- ✦ Optimize Continuous Monitoring Scheme
- ✦ Trend Supplier Quality
- ✦ Fine-tune performance metrics
- ✦ Statistically Establish Optimal Set points and Ranges

#### DOWNSTREAM QUALITY METRICS

##### Goals for New Products:

- ✦ Ensure Sustainable Commercialization
- ✦ Develop Detection and Predictive Models
- ✦ Establish forward-looking metrics
- ✦ Correlate quality data
- ✦ Establish Alert / Action Limits

##### Goals for Legacy Products:

- ✦ Elevate current trending practices
- ✦ Identify key focus areas
- ✦ Improve measurable characteristics

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS



### CGMP REQUIREMENTS

#### **21CFR 211 already requires trending of critical quality systems:**

- CAPA Effectiveness
- OOS Results
- Deviations
- OOTs
- Complaints

"A maximally efficient, agile, flexible, pharmaceutical manufacturing sector that reliably produces high quality drug products without extensive regulatory oversight."

Janet Woodcock Oct. 2005

- **FDA's newly published Guideline (Request for Quality Metrics Guidance, July 2015)**

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### ENTERPRISE-WIDE QUALITY SYSTEMS

- Improve Predictive Models for Scale-up
- Analyze critical supplier key data
  - Establish API supplier process and material characterization
  - Cell bank variability analysis
- Inter-lab Comparability Analysis
- Establish Equipment Statistical Control Practices
- **Apply Metrics and Statistics Throughout Lifecycle Process Validation—Stage 1, 2 and 3**



# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### UPSTREAM, MIDSTREAM AND DOWNSTREAM QUALITY METRICS

CONTROL VARIABLES OF GREATEST INFLUENCE | CREATE PREDICTIVE MODELS

### DESIGN A FRAMEWORK FOR AN ENTIRE PLATFORM OF AGILE ANALYTICS

- USE METRICS, DATA AND STATISTICAL ANALYSIS FOR EMPOWERED DECISION-MAKING
- CONNECT METRICS AND DATA DIRECTLY TO ITS CENTER OF CONTROL
- CREATE A SYNERGISTIC RELATIONSHIP BETWEEN DATA AND PERSONNEL

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

**UPSTREAM QUALITY METRICS FOR NEW PRODUCTS: SUPPORT SPEED TO MARKET**  
**CONTROL VARIABLES OF GREATEST INFLUENCE | CREATE PREDICTIVE MODELS**

**KEY STEPS:**


- Analyze existing data related to process
- Evaluate Stage 1—Process Design Strategy
- Customize measurement tools
  - Optimization of Good Process Monitoring Practices (GPMP)
  - Evaluate and monitor measurement process and tools
- Enhance Process Design Approach (QbD)
- Identify sources of variation
- Monitor to establish key indicators (Sift through outputs)
- Detect degree of variation and control it
- Deliver key indicators related to supplier, process and equipment
- Understand impact of variation and control it
- Control variation commensurate with risk it represents
- Establish downstream efficiencies and key areas of focus
- Prepare supplier and process dossiers for Stage 2—Process Qualification

**ULTIMATE OUTCOME: INCREASE VIABLE AND REDUCE NON-VIABLE DATA AT STAGE 1—PROCESS DESIGN**



# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS



### MIDSTREAM QUALITY METRICS - NEW PRODUCTS

ELIMINATE SUBMISSION ROADBLOCKS  
EXPEDITE SUBMISSION REVIEW PROCESS  
VERIFY PROCESS PERFORMANCE

- Align with Stage 2—Process Qualification
- Statistically Establish parameters, ranges and optimal operating conditions
- Understand criticality of parameters along a dynamic spectrum that uses 360°-metrics
- Statistically Monitor Equipment and Utility Performance
  - Establish Predicative Indices for utilities

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### **MIDSTREAM QUALITY METRICS - NEW PRODUCTS: ELIMINATE SUBMISSION ROADBLOCKS**

#### **EXPEDITE SUBMISSION REVIEW PROCESS | VERIFY PROCESS PERFORMANCE**

#### **KEY STEPS:**

- Analyze existing data related to production controls
- Evaluate Stage 2—Process Qualification Approach
- Customize measurement tools
  - Exercise Good Process Monitoring Practices (GPMP)
  - Evaluate and monitor measurement process and tools
  - Maintain awareness of measurement tools
- Monitor key indicators and ongoing operational data (including deviations)
- Ensure issues are resolved and controls are adjusted
- Monitor supplier, process and equipment variability (Control Charts)
- Establish risk management approach for known variations (reduce variability)
- Optimize efficiencies and key areas of focus
- Prepare production train for Stage 3—Continued Process Verification

**ULTIMATE OUTCOME: REDUCE NUMBER OF VALIDATION / PQ BATCHES REQUIRED AT PAI**

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### MIDSTREAM QUALITY METRICS – LEGACY PRODUCTS

#### SUSTAINABLE COMMERCIALIZATION

#### REFINE KEY QUALITY INDICATORS

#### OPTIMIZE PROCESS PERFORMANCE

- Align with Stage 2—Process Qualification
- Statistically Establish optimal set points, ranges and operating conditions
- Statistically Monitor Equipment and Utility Performance
  - Utilities / PM/ Calibration Data Reliability Analysis
  - Establish Predicative Index for utilities

- Establish Statistical Process Controls based on select historical data
- Fine-tune areas and levels of focus and monitoring
  - Process Performance Index (PPI)
  - Capabilities Performance Index (CPI)
- Environmental Monitoring Analysis
- Controlled Area Performance Assessment
- Method / Assay Variability Analysis

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### MIDSTREAM QUALITY METRICS – LEGACY PRODUCTS

#### SUSTAINABLE COMMERCIALIZATION | REFINE KEY QUALITY INDICATORS

#### OPTIMIZE PROCESS PERFORMANCE


##### KEY STEPS:

- Evaluate initial process validation approach
- Analyze existing data related to production controls
- Customize measurement tools
  - Install Good Process Monitoring Practices (GPMPs)
  - Evaluate and monitor measurement process and tools
  - Maintain awareness of measurement tools
- Monitor key indicators and ongoing operational data
- Ensure issues are resolved and controls are adjusted
- Monitor supplier, process and equipment variability (Control Charts)
- Establish risk management approach for known variations
- Optimize efficiencies and key areas of focus
- Ensure Stage 3—Continued Process Verification scheme provides viable and actionable data

**ULTIMATE OUTCOME: REDUCE NUMBER OF FDA INSPECTIONS, DRUG SHORTAGES AND COMPLIANCE CHALLENGES.**

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS



### DOWNSTREAM QUALITY METRICS – NEW AND LEGACY PRODUCTS:

**SUSTAINABLE COMMERCIALIZATION**  
**ELEVATE CURRENT TRENDING PRACTICES**  
**AUGMENT KEY QUALITY INDICATORS**  
**OPTIMIZE PROCESS PERFORMANCE**

- Align with Stage 3—Continuous Process Verification
- Statistically Monitor Corporate Audits: Internal and Supplier
  - Analyze SCAR Trends
- Equipment and Utility Performance
  - Utilities / PM/ Calibration Data Reliability Analysis
  - Establish Predictive Index for utilities


# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### DOWNSTREAM QUALITY METRICS – NEW AND LEGACY PRODUCTS:

**SUSTAINABLE COMMERCIALIZATION**  
**ELEVATE CURRENT TRENDING PRACTICES**  
**AUGMENT KEY QUALITY INDICATORS**  
**OPTIMIZE PROCESS PERFORMANCE**

- Establish meaningful metadata program
- Analyze OOS and OOT Trends
- Analyze non-conformances, CAPAs, and CAPA effectiveness
- Stability Data Analysis
- Environmental Monitoring Analysis
- Complaint Trending and Analysis



# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS

### DOWNSTREAM QUALITY METRICS – NEW AND LEGACY PRODUCTS:

SUSTAINABLE COMMERCIALIZATION

ELEVATE CURRENT TRENDING PRACTICES

AUGMENT KEY QUALITY INDICATORS

OPTIMIZE PROCESS PERFORMANCE

- Correlate Quality Data
- Improve Measurable Characteristics
- Refine Predicative Models
- Establish Alert & Action limits for Key Areas of Focus
- Continuous Improvement Optimization



# PAREXEL's

## ENTERPRISE-WIDE QUALITY METRICS PROGRAM

### DOWNSTREAM QUALITY METRICS – NEW AND LEGACY PRODUCTS:

SUSTAINABLE COMMERCIALIZATION | ELEVATE CURRENT TRENDING PRACTICES

OPTIMIZE KEY QUALITY INDICATORS | OPTIMIZE PROCESS PERFORMANCE

#### KEY STEPS:

- Install statistically-based Continuous Process Monitoring Scheme
  - Develop Platform Architecture to support Business analytics
- Design and implement pathways for information triage, risk identification and mitigation
- Fine-tune root-cause investigative and resolution techniques
  - Ensure timely reporting to internal and external stakeholders and regulators
- Continue to monitor key indicators and ongoing operational data
- Ensure controls are adjusted as needed
- Continue to monitor supplier, process and equipment variability
- Confirm effectiveness of risk management approach for known variations
- Confirm key indicators for performance, risk and compliance align with strategic objectives
- Ensure Stage 3—Continued Process Verification scheme provides viable and actionable data
- Evolve individual data streams and platform as needed

**ULTIMATE OUTCOME: REDUCE NUMBER OF FDA INSPECTIONS, DRUG SHORTAGES AND COMPLIANCE CHALLENGES.**



THANK YOU FOR YOUR TIME AND ATTENTION.

# PAREXEL

## ENTERPRISE-WIDE QUALITY METRICS



**CARMEN MEDINA, MPH, PhD**  
VP Technical

carmen.medina@PAREXEL.com  
t. 619.944.6137

**PAREXEL**<sup>®</sup>  
YOUR JOURNEY. OUR MISSION.™